<DOC>
	<DOCNO>NCT00345163</DOCNO>
	<brief_summary>This Phase II , open-label , multicenter , randomize , non comparative study consist two concurrent single-arms . Approximately 160 subject randomize 1:1 ratio Arm 1 ( bevacizumab alone ) Arm 2 ( bevacizumab + irinotecan ) .</brief_summary>
	<brief_title>A Study Evaluate Bevacizumab Alone Combination With Irinotecan Treatment Glioblastoma Multiforme ( BRAIN )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥ 18 year Histologically confirm GBM first second relapse Radiographic demonstration disease progression follow prior therapy Bidimensionally measurable disease minimum measurement 1 cm ( 10 mm ) one diameter MRI perform within 14 day prior first treatment ( Day 0 ) An interval ≥ 4 week since prior surgical resection Prior standard radiation GBM Prior chemotherapy : firstrelapse subject Prior chemotherapy : secondrelapse subject Recovery effect prior therapy , include follow : 4 week cytotoxic agent ( except 6 week nitrosoureas , 3 week procarbazine , 2 week vincristine ) ; 4 week investigational agent ; 1 week noncytotoxic agent ; 8 week radiotherapy minimize potential MRI change relate radiation necrosis might misdiagnosed progression disease , 4 week new lesion , relative preradiation MRI , develop outside primary radiation field Prior therapy gamma knife focal highdose radiation allow subject must subsequent histologic documentation recurrence , unless recurrence new lesion outside irradiated field Karnofsky performance status ≥ 70 Life expectancy &gt; 12 week Use effective mean contraception male females childbearing potential Ability comply study followup procedure Prior treatment irinotecan , bevacizumab , another VEGF VEGFRtargeted agent Prior treatment prolifeprospan 20 carmustine wafer Prior intracerebral agent Need urgent palliative intervention primary disease ( e.g. , impending herniation ) Evidence recent hemorrhage baseline MRI brain follow exception : Presence hemosiderin ; Resolving hemorrhagic change relate surgery ; Presence punctate hemorrhage tumor Received two treatment regimen Grade III and/or Grade IV glioma Blood pressure &gt; 150 mmHg systolic &gt; 100 mmHg diastolic History hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great CHF History myocardial infarction unstable angina within 6 month prior Day 0 History stroke transient ischemic attack within 6 month prior study enrollment Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 0 Evidence bleed diathesis coagulopathy History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 History intracerebral abscess within 6 month prior Day 0 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure ( exclude placement vascular access device ) , stereotactic biopsy , fine needle aspiration , core biopsy within 7 day prior Day 0 Serious nonhealing wound , ulcer , bone fracture Pregnancy ( positive pregnancy test ) lactation Known hypersensitivity component bevacizumab History malignancy within 5 year ( except nonmelanoma skin cancer carcinoma situ cervix ) Pregnant nursing female Unstable systemic disease , include active infection , uncontrolled hypertension , serious cardiac arrhythmia require medication Subjects unable undergo MRI contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Avastin</keyword>
	<keyword>Brain Cancer</keyword>
	<keyword>GBM</keyword>
</DOC>